Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350183 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ACASP3SENP7 | |
| SCHEMBL31372083 | 0.79 | HTR1A (0.42) | NPC1RAB9AALDH1A1MAPTMAPK1 | |
| SCHEMBL14029670 | 0.79 | CHRNB2 (0.39) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL22473503 | 0.79 | ADRA2A (0.40) | ALDH1A1MAPTGAATSHRHSD17B10 | |
| SCHEMBL20449129 | 0.78 | ADRA2A (0.47) | MAPTLMNACA12CA1CA9 | |
| SCHEMBL20449128 | 0.78 | ADRA2A (0.47) | MAPTLMNACA12CA1CA9 | |
| SCHEMBL4336961 | 0.77 | MAP3K14 (0.54) | SMN1; SMN2NPC1RAB9ACASP3SENP7 | |
| SCHEMBL4336968 | 0.77 | MAP3K14 (0.54) | SMN1; SMN2NPC1RAB9ACASP3SENP7 | |
| SCHEMBL28332237 | 0.77 | MAP3K14 (0.54) | SMN1; SMN2NPC1RAB9ACASP3SENP7 | |
| SCHEMBL13614278 | 0.77 | PDCD1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | SMN1; SMN2 2582/4885NPC1 734/4885RAB9A 3430/4885 |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | SMN1; SMN2 2002/4885NPC1 1392/4885RAB9A 3094/4885 |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | BDKRB1, BDKRB2, EDNRB | SMN1; SMN2 2201/4885NPC1 614/4885RAB9A 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.